Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mixed amfetamine salts - Takeda

Drug Profile

Mixed amfetamine salts - Takeda

Alternative Names: Amphetamine salts (mixed, long acting) - Takeda; d,l-Amphetamine and d-amphetamine salts (long acting) - Takeda; d,l-Amphetamine and dextroamphetamine salts (long acting) - Takeda; d-Amphetamine and d,l-amphetamine salts (long acting) - Takeda; Dextroamphetamine and d,l-amphetamine salts (long acting) - Takeda; Mydayis; SHP-465; SLI 381; SPD 465; Triple-bead mixed amphetamine salts - Takeda; Triple-bead-mixed-amfetamine-salts; Triple-bead-mixed-amphetamine-salts

Latest Information Update: 19 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire
  • Developer Takeda
  • Class Amphetamines; Behavioural disorder therapies
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 01 Feb 2019 Shire terminates a phase III trial for Attention-deficit hyperactivity disorder (In children, In adolescents) in USA due to efficacy reason (PO) (NCT03325894)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 05 Oct 2018 Shire completes a phase-I clinical trials in Attention-deficit hyperactivity disorder (In children) in USA (PO) (NCT03327402)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top